

REPORT

of the Investor Relations Director

of “Sopharma” AD for 2025

The activity of the Investor Relations Director is strictly regulated in the Law on Public offering of Securities (LPOS).

The main activities of the Director of Investor Relations in 2025 include:

1. creating documents and ensuring their storage in the relevant registers, including the minutes of the meetings of the Board of directors, the minutes of the General Meetings of the shareholders of the Company, the information, provided to the public and the internal rules for the operation of the Company, according to the requirements of art. 116d of LPOS;
2. effective communication and mediation between the Company and stakeholders, including relevant government institutions;
3. preparation and distribution of materials, containing important data and information about Sopharma Group, such as presentations, descriptions and information files for the media and others;
4. participation in the preparation and publication of all financial reports of the Company and all official announcements, simultaneously in Bulgarian and English, as well as condensed versions in Russian and Polish for the Company's website;
5. preparation of documents, organization and provision of the General Meetings of shareholders and warrant holders;
6. active dialogue with the investment community;
7. maintenance of the website of the Company, where improvements are continuously being made in the way the information is presented, in the organization of the site and the scope of the data provided in order to better present the activities of the Company;
8. support and provision of information to all departments in order to ensure adherence to the LPOS and all regulations, accompanying its application, as well as European capital markets legislation;
9. assistance and guidance to avoid conflicts of interest;
10. organization and participation in investor conferences and other events, that promote the activities of the Company.

This document is a translation of the original text in Bulgarian; in case of divergence the Bulgarian original is prevailing.

Submitting information to the Warsaw Stock Exchange:

In 2025, 265 notifications and documents were submitted to the Warsaw Stock Exchange as part of „Sopharma“ AD's regulatory obligations. This includes quarterly and annual reports, insider notifications, monthly results and others. This ensures equity for investors trading in shares on the Bulgarian and Warsaw Stock Exchanges.

Participation in projects:

In 2025, the Directorate was responsible for/participated in the following projects:

- Capital increase under condition through the last exercise of warrants from issue BG9200001212;
- Increase of the Company's capital with its own funds;
- Creation of a new website for the Company;
- Initial public offering of three warrant issues, etc.

National Corporate Governance Commission:

The IRD continues to support the Executive Director's work in connection with his activities as a member of the National Corporate Governance Commission as over the past year, the Commission updated the National Corporate Governance Code, the Scorecard of Companies in relation to the National Corporate Governance Code, and prepared a Monitoring Report on the state of corporate governance in Bulgaria in 2024.

Supporting the work of the Association of Bulgarian Investor Relations Directors:

The Investor Relations Director is a member of the Management board of the Association and assists with its activities in connection with the organization of trainings, meetings, conferences and drafting of opinions on relevant amendments in the legislation.

Bulgarian National Network of the UN Global Compact:

The Investor Relations Director represents the Company in the National Council of the Bulgarian Network of the UN Global Compact.

Monitoring of the changes in legislation related to the operations of the Company:

In 2025, the IRD took measures to implement all changes related to the Company's activities, such as new requirements for disclosure of material information, disclosure of the annual audited financial statements of public companies in accordance with the European Single Electronic Format, disclosure of climate-related information and so on.

Improvements in reporting:

In 2025, IRD continued to contribute to updating the Company's reporting documents, financial statements and all accompanying documents. All changes have been made in the direction of increasing

This document is a translation of the original text in Bulgarian; in case of divergence the Bulgarian original is prevailing.

investors' awareness and providing a complete and objective description of the Company's state and business.

Preparation and conducting of the general meetings of shareholders of the Company and meetings with the investment community:

In 2025, one Annual General Meeting and two Extraordinary General Meetings of the Shareholders of Sopharma AD were held.

Share capital:

As at December 31, 2025 the capital of “Sopharma” AD is BGN 539 157 603, divided into 539 157 603 dematerialized, freely transferable shares.

As at December 31, 2025 the Company's share capital was distributed among 6 742 shareholders. Out of them 142 are legal entities - 127 Bulgarian and 15 foreign legal entities holding a total of 84.59% of the Company's capital. Over 73 pension and investment funds are also shareholders and own a total of 16.01% of the Company's capital. Foreign investors represent 11.81% of all legal entities and hold a total of 2.82% of the Company's shares. 6 742 physical persons with a total of 15.41% of which Bulgarian - 99.38%, holding 15.29% of the Company's capital and foreign ones - 0.62%, owning 0.12% of the Company's capital are also shareholders in “Sopharma” AD.

The free float as at 31.12.2025 is 33.94%.

Treasury shares:

In accordance with the decision of the General Meeting of Shareholders from August 4, 2024 “Sopharma” AD buys back shares, as at 31 December 2025 a total of 13 624 541 shares representing 2.53% of the Company's capital were bought back.

Dividends:

At the Annual General Meeting of Shareholders held on 27 June 2025, “Sopharma” AD decided to distribute a dividend from the profit for the financial year 2025 in amount of BGN 8 stotinki per share.

The Extraordinary General Meeting held on 05 December 2025 decided to distribute a dividend to shareholders from the profit for the first half of 2025 in the amount of EUR 0.045 per share.

Trading in the Company's shares with ISIN BG11SOSOBT18:

On the "Bulgarian Stock Exchange" AD, the price of the shares in 2025 ranges between BGN 5.85 and BGN 6.37 (Warsaw Stock Exchange – 12.05 and 15.00 Polish zlotys, respectively). For the whole year, 3 988 905 lots were traded at a weighted average price of BGN 5.85. The total turnover of the "Bulgarian Stock Exchange" AD with shares of the Company for the year amounts to BGN 23.892 million or over 17.64% of the total annual turnover of the PREMIUM segment. The market capitalization of the Company at the end of the year is BGN 1 504 772 377.

/Signature/

Pelagia Viatcheva

Investor Relations Director